THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF CHLORPROPAMIDE

被引:2
|
作者
KALLIO, J
HUUPPONEN, R
PYYKKO, K
机构
[1] Departments of Pharmacology and Clinical Pharmacology, University of Turku
关键词
Chlorpropamide; Debrisoquine phenotype; Metabolism; Pharmacogenetics; Pharmacokinetics;
D O I
10.1007/BF02657068
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and urinary metabolite pattern of a single oral dose of chlorpropamide 250 mg have been studied in 6 extensive and 5 poor metabolizers of debrisoquine. Ammonium chloride was given orally to acidify the urine in order to make elimination of the parent drug dependent on metabolism alone. The concentration profile in serum and the pharmacokinetic parameters of the parent drug were similar in both groups. However, the ratio in urine of unchanged chlorpropamide to its hydroxylated metabolites was higher in poor than in extensive metabolizers. © 1990 Springer-Verlag.
引用
收藏
页码:93 / 95
页数:3
相关论文
共 50 条
  • [1] THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PROPRANOLOL
    LENNARD, MS
    JACKSON, PR
    FREESTONE, S
    TUCKER, GT
    RAMSAY, LE
    WOODS, HF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (06) : 679 - 685
  • [2] LACK OF RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF QUININE
    WANWIMOLRUK, S
    CHALCROFT, S
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (05) : 617 - 620
  • [3] PHARMACOKINETICS AND PHARMACODYNAMICS OF NIFEDIPINE AND DEBRISOQUINE OXIDATION PHENOTYPE
    LEWIS, RV
    JACKSON, PR
    RAMSAY, LE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 19 (04) : P562 - P562
  • [4] LACK OF RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS AND 1ST DOSE EFFECT OF PRAZOSIN
    LENNARD, MS
    MCGOURTY, JC
    SILAS, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (02) : 276 - 278
  • [5] LACK OF RELATIONSHIP BETWEEN TOLBUTAMIDE METABOLISM AND DEBRISOQUINE OXIDATION PHENOTYPE
    PEART, GF
    BOUTAGY, J
    SHENFIELD, GM
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 33 (04) : 397 - 402
  • [6] LACK OF RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE KINETICS OF TOLBUTAMIDE
    SHENFIELD, GM
    BOUTAGY, J
    PEART, GFD
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 116 - 116
  • [7] Relationship between debrisoquine oxidation phenotype and susceptibility to lung cancer
    Sardas, S
    Cok, I
    TOXICOLOGY, 2001, 164 (1-3) : 153 - 153
  • [8] OXIDATION PHENOTYPE - COMPARISON BETWEEN DEBRISOQUINE AND DEXTROMETHORPHAN TESTS
    VINCENTVIRY, M
    RICHE, I
    SIEST, G
    GALTEAU, MM
    CLINICAL CHEMISTRY, 1989, 35 (06) : 1184 - 1185
  • [9] DIGOXIN PHARMACOKINETICS AND DEBRISOQUINE METABOLIC PHENOTYPE
    HOU, ZY
    MEYER, PS
    SOLDIN, S
    SCHWARTZ, SL
    WOOSLEY, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 126 - 126
  • [10] STEREOSELECTIVE METABOLISM OF METOPROLOL IN CAUCASIANS AND NIGERIANS - RELATIONSHIP TO DEBRISOQUINE OXIDATION PHENOTYPE
    LENNARD, MS
    TUCKER, GT
    WOODS, HF
    SILAS, JH
    IYUN, AO
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (05) : 613 - 616